Stockholm3 for prostate cancer screening

Equality considerations

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others.

The technology is not suitable for people younger than 45 years or older than 74 years, or for people with a previous diagnosis of prostate cancer. The technology is suitable for transgender people.

People with an African family background have a high risk of prostate cancer (lifetime risk of approximately 1 in 4). The technology has been evaluated in Scandinavian populations (predominantly Caucasian). The summarised evidence showed limited data for Black, Asian and minority ethnic groups. The company submitted that this will be addressed by an ongoing clinical trial (ClinicalTrial.gov Identifier: NCT04583072).